MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 5.3% - Time to Sell?

Key Points

• MLTX shares fell 5.3% to about $16.41 in mid-day trading, with volume down 62% from its average session level.
• MoonLake reported positive Phase 3 results for sonelokimab in psoriatic arthritis, while expecting to complete another trial’s enrollment in the third quarter and submit a hidradenitis suppurativa application by September’s end.
• Despite improved-than-expected quarterly results and $537 million in liquidity, the company remains loss-making, insiders have recently sold shares, and analysts maintain an average “Hold” rating with a $24.21 price target.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report)'s stock price traded down 5.3% during mid-day trading on Tuesday . The company traded as low as $16.55 and last traded at $16.4080. 560,651 shares traded hands during mid-day trading, a decline of 62% from the average session volume of 1,463,796 shares. The stock had previously closed at $17.33.

Key Stories Impacting MoonLake Immunotherapeutics

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: Strong Phase 3 psoriatic arthritis results: MoonLake reported that sonelokimab met all primary and secondary clinical goals in the Phase 3 IZAR-1 trial at Week 16. In the 60 mg induction group, 42.1% of patients achieved ACR50, while ACR20 reached 66.5%; among patients with skin involvement, 61% achieved PASI90 and 41.2% achieved minimal disease activity. The results support the drug’s potential in psoriatic arthritis and could strengthen its regulatory and commercial outlook. Reuters article
• Positive Sentiment: Improved financial result and ample liquidity: Second-quarter adjusted results included a loss of $0.84 per share, narrower than the $0.92 analyst consensus. MoonLake ended the quarter with $537 million in cash, cash equivalents and short-term marketable securities, expects its cash runway to extend through mid-2028, and said up to $400 million remains available under its Hercules Capital facility. MoonLake Q2 results article
• Positive Sentiment: Upcoming catalysts: MoonLake expects to complete IZAR-2 enrollment in the third quarter of 2026 and submit a biologics license application for sonelokimab in hidradenitis suppurativa by the end of September.
• Neutral Sentiment: Options activity increased: Traders purchased 2,707 call options, about 142% above typical daily volume, indicating heightened interest and potentially bullish speculation, though options activity does not confirm sustained buying in the shares.
• Neutral Sentiment: Analyst stance remains cautious: Brokerages give MLTX an average “Hold” recommendation, suggesting the positive trial data may already be partly reflected in valuation.
• Negative Sentiment: Ongoing losses and insider selling: MoonLake reported a $61.8 million quarterly net loss, including $50.2 million in research and development expenses. Separately, company insiders reportedly made no open-market purchases and sold shares in the past six months, which may weigh on investor sentiment.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of MoonLake Immunotherapeutics in a report on Friday. Needham & Company LLC upped their price objective on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a "buy" rating in a research note on Tuesday, May 12th. BTIG Research restated a "buy" rating and set a $30.00 target price on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 9th. HC Wainwright reaffirmed a "buy" rating and issued a $45.00 target price on shares of MoonLake Immunotherapeutics in a research note on Monday, July 20th. Finally, Leerink Partners boosted their price target on MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an "outperform" rating in a report on Wednesday, July 1st. Ten investment analysts have rated the stock with a Buy rating, four have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $24.21.

MoonLake Immunotherapeutics Price Performance

The company has a market capitalization of $1.19 billion, a PE ratio of -4.20 and a beta of 1.06. The company has a current ratio of 8.60, a quick ratio of 8.60 and a debt-to-equity ratio of 0.39. The company's 50 day moving average price is $19.02 and its 200-day moving average price is $17.89.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.08. On average, sell-side analysts forecast that MoonLake Immunotherapeutics will post -3.64 earnings per share for the current fiscal year.

Insider Transactions at MoonLake Immunotherapeutics

In other news, insider Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $19.43, for a total value of $971,500.00. Following the transaction, the insider directly owned 2,824,551 shares of the company's stock, valued at $54,881,025.93. The trade was a 1.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Da Silva Jorge Santos sold 68,289 shares of the stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $20.02, for a total transaction of $1,367,145.78. Following the sale, the chief executive officer directly owned 2,774,893 shares of the company's stock, valued at approximately $55,553,357.86. This trade represents a 2.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 344,800 shares of company stock worth $6,820,071. Company insiders own 10.40% of the company's stock.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Several institutional investors have recently bought and sold shares of the business. Kestra Advisory Services LLC purchased a new position in shares of MoonLake Immunotherapeutics in the 4th quarter valued at $26,000. Bank of America Corp DE boosted its position in MoonLake Immunotherapeutics by 64.7% during the 3rd quarter. Bank of America Corp DE now owns 4,532 shares of the company's stock worth $32,000 after purchasing an additional 1,781 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in MoonLake Immunotherapeutics by 115.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company's stock valued at $42,000 after purchasing an additional 3,166 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in MoonLake Immunotherapeutics by 45.4% in the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company's stock valued at $45,000 after purchasing an additional 1,069 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in MoonLake Immunotherapeutics in the fourth quarter valued at about $47,000. 93.85% of the stock is currently owned by hedge funds and other institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source